Chikungunya - Pipeline Review, H1 2016
SKU ID :GMD-10160995 | Published Date: 20-Apr-2016 | No. of pages: 90Description
TOC
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chikungunya Overview 10
Therapeutics Development 11
Pipeline Products for Chikungunya – Overview 11
Pipeline Products for Chikungunya – Comparative Analysis 12
Chikungunya – Therapeutics under Development by Companies 13
Chikungunya – Therapeutics under Investigation by Universities/Institutes 15
Chikungunya – Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Chikungunya – Products under Development by Companies 18
Chikungunya – Products under Investigation by Universities/Institutes 19
Chikungunya – Companies Involved in Therapeutics Development 20
Abivax S.A. 20
Arbovax, Inc. 21
Arno Therapeutics, Inc. 22
Bharat Biotech International Limited 23
Etubics Corporation 24
Indian Immunologicals Limited 25
Inovio Pharmaceuticals, Inc. 26
Integral Molecular, Inc. 27
Integrated BioTherapeutics, Inc. 28
Merck & Co., Inc. 29
Nanotherapeutics, Inc. 30
PaxVax, Inc. 31
Profectus BioSciences, Inc. 32
Takeda Pharmaceutical Company Limited 33
Themis Bioscience GmbH 34
Valneva SE 35
Chikungunya – Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ABX-309 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Antibody for Chikungunya - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AR-12 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chikungunya (viral like particles) vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
chikungunya vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chikungunya vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
chikungunya vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
chikungunya vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
chikungunya vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chikungunya vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
chikungunya vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
chikungunya vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
chikungunya vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
chikungunya vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
chikungunya vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
chikungunya vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
chikungunya vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
chikungunya vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
chikungunya vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DEF-201 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IMCKV-063 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Monoclonal Antibodies for Chikungunya - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Monoclonal Antibody for Chikungunya - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MV-CHIK - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Chikungunya – Recent Pipeline Updates 76
Chikungunya - Dormant Projects 80
Chikungunya – Product Development Milestones 81
Featured News & Press Releases 81
Mar 22, 2016: Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study 81
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 82
Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 84
Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 84
Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1 85
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 86
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 87
Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 87
Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 88
Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90
Tables & Figures
List of Tables
Number of Products under Development for Chikungunya, H1 2016 11
Number of Products under Development for Chikungunya – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Chikungunya – Pipeline by Abivax S.A., H1 2016 20
Chikungunya – Pipeline by Arbovax, Inc., H1 2016 21
Chikungunya – Pipeline by Arno Therapeutics, Inc., H1 2016 22
Chikungunya – Pipeline by Bharat Biotech International Limited, H1 2016 23
Chikungunya – Pipeline by Etubics Corporation, H1 2016 24
Chikungunya – Pipeline by Indian Immunologicals Limited, H1 2016 25
Chikungunya – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 26
Chikungunya – Pipeline by Integral Molecular, Inc., H1 2016 27
Chikungunya – Pipeline by Integrated BioTherapeutics, Inc., H1 2016 28
Chikungunya – Pipeline by Merck & Co., Inc., H1 2016 29
Chikungunya – Pipeline by Nanotherapeutics, Inc., H1 2016 30
Chikungunya – Pipeline by PaxVax, Inc., H1 2016 31
Chikungunya – Pipeline by Profectus BioSciences, Inc., H1 2016 32
Chikungunya – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 33
Chikungunya – Pipeline by Themis Bioscience GmbH, H1 2016 34
Chikungunya – Pipeline by Valneva SE, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Stage and Target, H1 2016 38
Number of Products by Stage and Mechanism of Action, H1 2016 40
Number of Products by Stage and Route of Administration, H1 2016 42
Number of Products by Stage and Molecule Type, H1 2016 44
Chikungunya Therapeutics – Recent Pipeline Updates, H1 2016 76
Chikungunya – Dormant Projects, H1 2016 80
List of Figures
Number of Products under Development for Chikungunya, H1 2016 11
Number of Products under Development for Chikungunya – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Top 10 Targets, H1 2016 37
Number of Products by Stage and Top 10 Targets, H1 2016 37
Number of Products by Top 10 Mechanism of Actions, H1 2016 39
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39
Number of Products by Routes of Administration, H1 2016 41
Number of Products by Stage and Routes of Administration, H1 2016 41
Number of Products by Top 10 Molecule Types, H1 2016 43
Number of Products by Stage and Top 10 Molecule Types, H1 2016 43
Companies
Abivax S.A.
Arbovax, Inc.
Arno Therapeutics, Inc.
Bharat Biotech International Limited
Etubics Corporation
Indian Immunologicals Limited
Inovio Pharmaceuticals, Inc.
Integral Molecular, Inc.
Integrated BioTherapeutics, Inc.
Merck & Co., Inc.
Nanotherapeutics, Inc.
PaxVax, Inc.
Profectus BioSciences, Inc.
Takeda Pharmaceutical Company Limited
Themis Bioscience GmbH
Valneva SE
- PRICE
-
$2000$6000